Inditrade Cap. (532745)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Price-to-book of 0.60 offers a 40% discount to stated book value of ₹27.33 per share
• Market cap of ₹38 Cr is small, so even a focused asset sale or restructuring could be meaningful
• Stock has risen from its 52-week low of ₹2.49 to ₹16.45, indicating some market interest in a possible recovery
• Positive book value per share still exists despite the severe losses

Concerns

• ROE of -37.43% and ROCE of -31.28% show serious capital destruction
• Latest quarterly net loss of ₹96 Cr is more than 2.5 times the entire market cap of ₹38 Cr
• Sales growth of -124.96% and quarterly sales of -₹10 Cr point to a broken or reversed revenue model
• Piotroski F-Score of 2/9 signals financial distress, and promoter holding data is missing

AI Analysis

As a value investor, I first look for businesses that can earn a decent return on equity. Inditrade Cap fails that test outright: ROE is -37.43% and ROCE is -31.28%, meaning the company is actively destroying shareholder capital. The P/B ratio of 0.60 and book value of ₹27.33 against a price of ₹16.45 could look like a margin of safety, but a cheap price becomes a trap when the engine is heading toward a cliff. The latest quarter reports sales of -₹10 Cr and a net loss of -₹96 Cr. That loss is more than two and a half times the entire market cap of ₹38 Cr. A business cannot survive many such quarters. Graham taught me to focus on facts, not hope. The Piotroski F-Score of 2/9 is a red flag; it suggests very weak operating efficiency and financial health. Sales growth of -124.96% and profit growth of -3238.02% are not a temporary hiccup; they indicate a structural breakdown. With no dividend, the shareholder gets no cash flow while waiting for recovery. Promoter holding is not disclosed, which reduces my confidence in alignment. The 52-week range of ₹2.49 to ₹16.45 is astonishing; the stock has already risen sharply, so I would be paying near the top of a speculative move, not the bottom. This feels like a possible asset play because the price is below book value, but only if the book value is real and not impaired. Given the enormous quarterly loss, book value may be overstated or at risk. I would need to understand whether the ₹96 Cr loss is a one-time write-down or recurring operational bleeding. If recurring, the equity cushion will vanish quickly. In its present form, this is not a business I would buy; it is a melting ice cube, not a cheap cigar with one puff left.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer